Clinical trial supply logistics moves the investigational medicinal product, the drug being tested, and its comparator, an existing approved drug used for comparison, from packaging sites through regional depots to clinical trial sites and, for some trials, directly to a patient's home. Both products typically travel blinded: repackaged and relabeled so that neither the patient nor site staff can tell which one they are handling. That blinding requirement runs alongside the ordinary cold chain job of holding temperature, and the two constraints have to be solved together, not separately.
A commercial drug shipment optimizes for cost and speed once the product is approved and demand is predictable. A trial shipment optimizes for evidence integrity first, because an unblinded patient, a compromised sample, or an unreconciled dose can put at risk data that took years and an irreplaceable patient population to generate. The temperature band itself varies by product, a small molecule tablet may travel at room temperature while a biologic investigational product needs a tight 2-8°C hold, but the blinding and reconciliation demands sit on top of that band regardless of what it is.
Comparator handling has to mirror the investigational product
The comparator is usually a marketed drug purchased commercially and then over-encapsulated, re-blistered, or relabeled to look identical to the investigational product. Both then have to be packaged, monitored, and handled identically for the length of the trial, including how a temperature excursion is handled at a depot or site. If staff can source a replacement comparator faster than a replacement investigational unit, that visible difference in resupply speed can itself signal to an attentive site team which arm a patient is in, which is a real and often underestimated way a blind gets broken. Sourcing the comparator can also be the harder logistics problem of the two: a commercial product bought on the open market has its own batch and expiry history to track, on top of whatever repackaging the trial protocol demands.
Depot networks absorb unpredictable demand
Trial enrollment is inherently unpredictable: site activation is delayed, screening failure rates vary, and dosing schedules shift as the trial runs. A regional depot network holds buffer stock closer to sites than the original manufacturing site, so a site can be resupplied quickly without the sponsor mass-producing investigational product against a demand curve nobody can forecast accurately. Interactive response systems track site-level stock and trigger automatic resupply shipments once inventory crosses a threshold, which keeps the buffer as small as the unpredictability allows rather than padded against a worst case guess. Regional depots also shorten the customs and import path into each country a trial runs in, which matters more for a temperature-sensitive shipment than for a stable one, since every extra day in transit or at a border draws down the same finite cold chain window.
Returns, reconciliation, and destruction
Every dispensed, returned, and destroyed unit of investigational product has to reconcile against what was shipped out, a drug accountability record regulators inspect directly. Unused or expired product is typically shipped back to a depot or a destruction vendor rather than discarded at the site, so the paper trail stays intact and every unit is accounted for. This matters for two separate reasons: it protects patients from receiving product outside its verified temperature history, and it is one of the controls that detects diversion of an investigational drug outside the trial. A site that cannot reconcile every unit at an inspection risks the trial's data being questioned, not just the missing dose.
Direct-to-patient trials and the excursion decision
Decentralized trials increasingly ship investigational product straight to a patient's home instead of routing every dose through a site visit, which cuts travel burden for the patient considerably. It fits well for a stable oral drug that tolerates ambient shipping. It fits poorly for a fragile biologic on a tight 2-8°C window, because a residential delivery has no trained pharmacist standing by to receive the box, read the data logger, and act within hours if it shows an excursion. Sites and depots increasingly lean on active packaging and validated insulated shippers to widen that margin for error on both site and home deliveries.
When an excursion is flagged, the decision that follows is rarely an automatic discard. Investigational product at that stage of manufacture is often irreplaceable in the short term, so the standard response is to quarantine the affected units and query the sponsor's quality team against the stability data, weighing a possibly still-usable dose against dosing a patient with unverified product. Sponsors, contract research organizations, depot and third-party logistics networks, site pharmacists, and the regulatory bodies overseeing trial conduct all depend on that reconciliation working.